A drug used in patients in the early stage of the most common kind of breast cancer significantly reduced the risk of the disease returning after treatment, according to a new study
A drug used in people in the early stage of the most common kind of breast cancer – HR+/HER2- breast cancer – significantly reduced the risk of the cancer returning after treatment, according to a new study. The US Food and Drug Administration approved the Novartis drug ribociclib, marketed under the brand name Kisqali, in 2017 for people with cancer that has spread to other parts of the body, helping them live longer by slowing the disease’s growth and spread.
It is priced up to $15,000 a month, according to a recent analysis that suggested it was not a cost-effective treatment, even in its current use in people with advanced cancer. But a large number of people stand to benefit from such a drug. About 90% of patients who have breast cancer are diagnosed in the early stages.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
US court to hear challenge over Prince Harry's visa following drug revelations | CNNPrince Harry’s US immigration records should be unsealed in the light of revelations about drug-taking in his recent book, a conservative think tank will argue in a federal court next week.
Baca lebih lajut »
With no more Covid restrictions, Asia's drug cartels are thriving, UN report warns | CNNThe synthetic drug trade in Asia is roaring to “extreme levels,” with crime groups establishing new trafficking routes to evade enforcement crackdowns and methamphetamine prices hitting fresh lows, according to a new report released Friday.
Baca lebih lajut »
Naylor HR and 6 RBIs highlights Guardians' rare power surge in 12-8 win over OriolesJosh Naylor homered, had a career-high four hits and drove in six runs to highlight a rare power display by the Cleveland Guardians in a 12-8 victory over the Baltimore Orioles.
Baca lebih lajut »
Growing climate tech firms need engineers — but also sales and HR prosIn California, software engineering is the most in-demand kind of role. In Texas, it’s sales and business development, while in New York it’s operations.
Baca lebih lajut »
Novartis drug cuts recurrence risk by 25% in early-stage breast cancerNovartis breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly .
Baca lebih lajut »